Related Experiment Video

Updated: May 10, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death

Peng Jiao, Yun-Sheng Zhou, Juan-Xia Yang

    Molecular and Cellular Biochemistry
    |June 26, 2013
    PubMed

    Insights

    MK-2206, an AKT inhibitor, halts HepG2 cell growth by inducing G1-phase arrest and apoptosis. It also sensitizes TRAIL-resistant cells, offering a promising strategy for hepatocellular carcinoma (HCC) treatment.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Biochemistry

    Background:

    • AKT inhibitors show promise in cancer therapy.
    • Hepatocellular carcinoma (HCC) remains a significant health concern.
    • Understanding novel AKT inhibitors' mechanisms is crucial for effective treatment.

    Purpose of the Study:

    • To investigate the anticancer effects of MK-2206 on HepG2 cells.
    • To determine if MK-2206 enhances the apoptosis-inducing potential of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    • To elucidate the molecular mechanisms underlying MK-2206's action.

    Main Methods:

    • Cell viability assessed by MTT and colony formation assays.
    • Cell cycle analysis using propidium iodide flow cytometry.
    • Apoptosis determined by AnnexinV-FITC/PI staining and caspase/PARP cleavage assays.
    • Western blotting for protein expression analysis.
    • Inhibition of p38 kinase using SB203580.

    Main Results:

    • MK-2206 induced G1-phase arrest, decreasing cyclin D1 and increasing p21/p27 expression.
    • MK-2206 triggered concentration-dependent apoptosis via pro-caspase cleavage.
    • Activation of p38 kinase and JNK pathways was observed.
    • SB203580 partially inhibited MK-2206-induced cell death and caspase activation.
    • Combination of MK-2206 with TRAIL significantly inhibited TRAIL-resistant HepG2 cell growth.

    Conclusions:

    • MK-2206 exhibits potent anticancer activity against HepG2 cells through cell cycle arrest and apoptosis induction.
    • MK-2206 activates p38 and JNK pathways, contributing to its cytotoxic effects.
    • MK-2206 acts as a sensitizer to TRAIL, enhancing TRAIL-induced apoptosis.
    • MK-2206 represents a promising therapeutic agent for hepatocellular carcinoma, particularly in combination with TRAIL.

    More Related Videos

    Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

    Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

    Published on: March 30, 2019

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    MAPK Signaling Cascades01:07

    MAPK Signaling Cascades

    Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...